DelveInsight's "Age-related Macular Degeneration (AMD) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Age-related Macular Degeneration (AMD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The DelveInsight Age-related Macular Degeneration (AMD) epidemiology report gives a thorough understanding of the Age-related Macular Degeneration (AMD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Age-related Macular Degeneration (AMD) in the US, Europe, and Japan. The report covers the detailed information of the Age-related Macular Degeneration (AMD) epidemiology scenario in seven major countries (US, EU5, and Japan).
The Age-related Macular Degeneration (AMD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Age-related Macular Degeneration (AMD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Age-related Macular Degeneration (AMD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Age-related Macular Degeneration (AMD) epidemiology covered in the report provides historical as well as forecasted Age-related Macular Degeneration (AMD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
The DelveInsight Age-related Macular Degeneration (AMD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
The Age-related Macular Degeneration (AMD) Epidemiology report will allow the user to -
1. Key Insights
2. Executive Summary of Age-related Macular Degeneration (AMD)
3. Age-related Macular Degeneration (AMD): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
5.4.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in Germany (2019- 2032)
5.5.2. France Epidemiology
5.5.2.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in France (2019- 2032)
5.5.3. Italy Epidemiology
5.5.3.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in Italy (2019- 2032)
5.5.4. Spain Epidemiology
5.5.4.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in Spain (2019- 2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. Age-related Macular Degeneration (AMD) Epidemiology Scenario in Japan (2019- 2032)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Age-related Macular Degeneration (AMD) Treatment and Management
6.2. Age-related Macular Degeneration (AMD) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
List of Tables
Table 1: Age-related Macular Degeneration (AMD) Epidemiology in 7MM (2019-2032)
Table 2: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Age-related Macular Degeneration (AMD) Epidemiology in the United States (2019-2032)
Table 4: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Age-related Macular Degeneration (AMD) Epidemiology in Germany (2019-2032)
Table 6: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Age-related Macular Degeneration (AMD) Epidemiology in France (2019-2032)
Table 8: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Age-related Macular Degeneration (AMD) Epidemiology in Italy (2019-2032)
Table 10: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Age-related Macular Degeneration (AMD) Epidemiology in Spain (2019-2032)
Table 12: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Age-related Macular Degeneration (AMD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Age-related Macular Degeneration (AMD) Epidemiology in Japan (2019-2032)
Table 16: Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Japan (2019-2032)
List of Figures
Figure 1 Age-related Macular Degeneration (AMD) Epidemiology in 7MM (2019-2032)
Figure 2 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Age-related Macular Degeneration (AMD) Epidemiology in the United States (2019-2032)
Figure 4 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Age-related Macular Degeneration (AMD) Epidemiology in Germany (2019-2032)
Figure 6 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Age-related Macular Degeneration (AMD) Epidemiology in France (2019-2032)
Figure 8 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Age-related Macular Degeneration (AMD) Epidemiology in Italy (2019-2032)
Figure 10 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Age-related Macular Degeneration (AMD) Epidemiology in Spain (2019-2032)
Figure 12 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Age-related Macular Degeneration (AMD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Age-related Macular Degeneration (AMD) Epidemiology in Japan (2019-2032)
Figure 16 Age-related Macular Degeneration (AMD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report
